Spaner DE - Search Results

1

Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.

Oppermann S, Lam AJ, Tung S, Shi Y, McCaw L, Wang G, Ylanko J, Leber B, Andrews D, Spaner DE. Oppermann S, et al. Among authors: spaner de. Oncotarget. 2016 Nov 8;7(45):72608-72621. doi: 10.18632/oncotarget.11618. Oncotarget. 2016. PMID: 27579615 Free PMC article.

2

Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.

Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, Imrie K, Spaner DE. Gitelson E, et al. Among authors: spaner de. Clin Cancer Res. 2003 May;9(5):1656-65. Clin Cancer Res. 2003. PMID: 12738718

3

Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy.

Spaner DE, Hammond C, Mena J, Shi Y. Spaner DE, et al. Br J Haematol. 2004 Dec;127(5):531-42. doi: 10.1111/j.1365-2141.2004.05240.x. Br J Haematol. 2004. PMID: 15566356 Free article.

4

Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells.

Hammond C, Shi Y, Mena J, Tomic J, Cervi D, He L, Millar AE, Debenedette M, Schuh AC, Baryza JL, Wender PA, Radvanyi L, Spaner DE. Hammond C, et al. Among authors: spaner de. J Immunother. 2005 Jan-Feb;28(1):28-39. doi: 10.1097/00002371-200501000-00004. J Immunother. 2005. PMID: 15614042

5

Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod.

Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Spaner DE, et al. Leuk Lymphoma. 2005 Jun;46(6):935-9. doi: 10.1080/10428190500054426. Leuk Lymphoma. 2005. PMID: 16019542

6

Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.

Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, He L, Tomai MA, Miller RL, Booth J, Radvanyi L. Spaner DE, et al. Leukemia. 2006 Feb;20(2):286-95. doi: 10.1038/sj.leu.2404061. Leukemia. 2006. PMID: 16341037

7

Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.

Tomic J, White D, Shi Y, Mena J, Hammond C, He L, Miller RL, Spaner DE. Tomic J, et al. Among authors: spaner de. J Immunol. 2006 Mar 15;176(6):3830-9. doi: 10.4049/jimmunol.176.6.3830. J Immunol. 2006. PMID: 16517754

8

Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.

Spaner DE, Masellis A. Spaner DE, et al. Leukemia. 2007 Jan;21(1):53-60. doi: 10.1038/sj.leu.2404456. Epub 2006 Oct 26. Leukemia. 2007. PMID: 17066089 Review.

9

Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents.

Shi Y, White D, He L, Miller RL, Spaner DE. Shi Y, et al. Among authors: spaner de. Cancer Res. 2007 Feb 15;67(4):1823-31. doi: 10.1158/0008-5472.CAN-06-2381. Cancer Res. 2007. PMID: 17308125

10

Extracellular calcium sensing promotes human B-cell activation and function.

Hammond CM, White D, Tomic J, Shi Y, Spaner DE. Hammond CM, et al. Among authors: spaner de. Blood. 2007 Dec 1;110(12):3985-95. doi: 10.1182/blood-2007-05-088468. Epub 2007 Aug 27. Blood. 2007. PMID: 17724142 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters